ERBB2 and breast cancer: In a recent study, researchers explored the efficacy and safety of pyrotinib plus TAC for HER2 + BC.36 Overall, 37.0% of patients achieved total pCR, 37.0% pCR in the breast, and 85.2% pCR in lymph node.